Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Expanding research and development of naturally-derived psilocybin for future FDA IND-enabling and clinical studies TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announceContinue reading “Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds”

Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory

Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies  – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce it has begun cultivating Psilocybe mushrooms, for theContinue reading “Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory”

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

– Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market (“NASDAQ”). As part of this up-listing strategy in the United States, MindMed has submitted an application to list its subordinate voting shares on NASDAQ. Continue reading “MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor”

PSYC Revamps Their Online Presence with a Relaunch of Corporate Website

— Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce that the Company has completed the redevelopment and relaunch of its corporate website; www.globaltracsolutions.com with the intent of showcasing PSYC’s emergence as a digital media leader within the expanding medicinal psychedelic industry. Earlier this year, the Company began the process ofContinue reading “PSYC Revamps Their Online Presence with a Relaunch of Corporate Website”

Numinus Announces Closing of Oversubscribed $4.6 Million Offering

– Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise of the agent’s option in its entirety in the form of units of the Company (each, a “Unit“). A total of 18,400,000 UnitsContinue reading “Numinus Announces Closing of Oversubscribed $4.6 Million Offering”

Liberty Leaf to Acquire Nova Mentis Biotech Corp. – Liberty Leaf Augments Portfolio with Entrance into the Emerging Psilocybin Therapy Market

– Liberty Leaf Holdings Ltd. (CSE: LIB) (FSE: HN3P) (OTCPK: LIBFF) (“LIB” or the “Company”) is pleased to announce that it has entered into an agreement (the “Agreement”) with Nova Mentis Biotech Corp. (“NOVA”), pursuant to which LIB will acquire, by way of share exchange, 100 per cent of all of the issued and outstanding securitiesContinue reading “Liberty Leaf to Acquire Nova Mentis Biotech Corp. – Liberty Leaf Augments Portfolio with Entrance into the Emerging Psilocybin Therapy Market”

CORRECTION: Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms

VANCOUVER, BC, June 11, 2020 /CNW/ – Numinus Wellness Inc. (TSX-V: NUMI) (“Numinus” or the “Company”) wishes to correct the original news release dated June 11, 2020 that contained the following errors: the Multidisciplinary Association for Psychedelic Studies (MAPS) conducts research using psychedelic substances in relation to mental health conditions, but is primarily focussed on MDMA for Post-Traumatic StressContinue reading “CORRECTION: Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms”

Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado

VANCOUVER, British Columbia, June 2, 2020 /CNW/ —  NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE: 0NF) (“NewLeaf Brands” or the “Company“), soon to put into effect its name change to Mydecine Group, is pleased to announce the completion of its wholly-owned and operated world class R&D Lab and Facilities focused on the mycology of the  fungtional© mushroom space. Earlier lastContinue reading “Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado”

Newleaf Brands Announces Newest Newleaf Brands Advisor Appointee, Dr. Aubrey Oliver, set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts

VANCOUVER, British Columbia, May 26, 2020 /PRNewswire/ — NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE: 0NF) (“NewLeaf Brands” or the “Company“) is pleased to announce that it has officially appointed Dr. Aubrey Oliver ND, RBT to be its newest advisor. Dr. Oliver is a Jamaican registered Functional Holistic doctor and a graduate of Ashford University in Complementary and Alternative Medicine. InContinue reading “Newleaf Brands Announces Newest Newleaf Brands Advisor Appointee, Dr. Aubrey Oliver, set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts”